new post
StocksRunner logo
mail
search
 
menu
 
Royalty Pharma plc
$46.90
-1.22%
 
  Set Alerts  
  
  Overview  
  
  Comments  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Headlines  
 

RPRX Stock Analysis & IQ Rating | Royalty Pharma plc

 
 

RPRX

 

Royalty Pharma plc

$46.90

 
-$0.57 | -1.22%
 
Set Alerts
 
  Overview  
  
  Comments  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Headlines  
 
 
52W High
$47.5
 
 
MKT CAP
$26.89B
 
52W Low
$29.66
 
 
VOL
$316.71K
 
P/E Ratio
N/A
 
 
AVG VOL
$3.80M
 
RSI
73.90
 
 
TREND
Uptrend
 
 
 

RPRX Stock IQ

 
lock  Login to see Royalty Pharma plc (RPRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
 
 

RPRX Target Price

 
 
 

Strengths

 
 

RPRX Rewards

 Earnings are forecast to grow

RPRX Rewards

 Pays a reliable dividend

 
 

RPRX Price Performance

 
 

$42.96   (+9.17%)

$39.15   (+19.80%)

$36.12   (+29.84%)

$33.41   (+40.38%)

 
 
1year
6month
3month
1month

RPRX Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

Earnings

×

Earnings

RPRX Earnings Sentiment Above analyst estimates

Rating

×

Rating

Momentum

×

Momentum

RPRX Momentum Analysis Has been gaining momentum

Activity

×

Activity

RPRX Activity Sentiment Pays a reliable dividend

Future

×

Future

RPRX Future Sentiment Earnings are forecast to grow
RPRX Analysts Opinion

RPRX Analysts opinion is positive and also has improved from the past 3 months

RPRX Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

100%
Consensus Rating
NA
Buy
Opinion
NA
Trend
Score
100%
Potential
Score
RPRX Street Sentiment

RPRX Street Sentiment is extremely bullish and have positive views on the near-term outlook

RPRX Risk Level

RPRX has Low risk level

RPRX Risk Level
Low
LOW
HIGH

RPRX Performance Sentiment

Sentiments overview associated with events and the stock performance

100%
Positive
10 out of 10
events present
0%
Negative
0 out of 10
events present
Very Bullish
Bullish
Neutral
Bearish
Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price
$41.38
Resistance Price
$47.47
Current Price Range
$47.47
$41.38
$47.47
Show methods +
 
 

Analyst Consensus

 

Recent Upgrades and Downgrades

 
 
100%
Consensus Rating
STRONG BUY
4
Buy
0
Hold
0
Sell
Date
Action
Rating
Firm

Feb 10, 2026

 

Upgrade

 

Buy

 

Citi

 

Dec 12, 2025

 

Reiterate

 

Buy

 

TD Cowen

 

Oct 11, 2025

 

Reiterate

 

Overweight

 

Morgan Stanley

 

Sep 30, 2025

 

Initiate

 

Buy

 

Goldman Sachs

 
 
 
Runners Also Watch
Close Price
Change
 

TEVA

Teva Pharma

32.15

-4.65%

 

ZYME

Zymeworks Commo

23.94

+0.51%

 
 
 
RPRX Latest Analysis +
 
 
FAQ About RPRX Stock Insights
 

What is RPRX current stock price?

What are RPRX stock strengths?

What is RPRX Risk Level?

What is RPRX market cap and volume?

What is RPRX current Stock IQ?

Should I buy RPRX stock right now?

Is RPRX a Strong Buy right now?

What does a 'Strong Buy' rating mean for RPRX?

What does a 'Strong Sell' rating mean for RPRX?

What factors influence RPRX's Stock IQ?

 
 
StocksRunner

Explore our RPRX Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored RPRX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our RPRX Daily Alerts

Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
 
 

RPRX

 

Royalty Pharma plc

 
Set Alerts
 
 

Current Price

 

$46.90

 
-$0.57 | -1.22%
 
 
52W High
$47.5
 
 
MKT CAP
$26.89B
 
52W Low
$29.66
 
 
VOL
$316.71K
 
P/E Ratio
N/A
 
 
AVG VOL
$3.80M
 
RSI
73.90
 
 
TREND
Uptrend
 
 
 
  Overview  
  
  Comments  
  
  Insights  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
 
 
 

Runners Also Watch

 
 
 
Symbol
Close
Change
 

TEVA

Teva Pharma

32.15

-4.65%

 

ZYME

Zymeworks Commo

23.94

+0.51%

 
 
 
 
 
user
 
 
 
 

RPRX Price Performance

 
 

$42.96   (+9.17%)

$39.15   (+19.80%)

$36.12   (+29.84%)

$33.41   (+40.38%)

 
 
1year
6month
3month
1month
 

RPRX Analysts Opinion

Overall standing per market and analyst expectations. menu Hover over the category for more information

Earnings

×

Earnings

RPRX Earnings Sentiment Above analyst estimates

Rating

×

Rating

Momentum

×

Momentum

RPRX Momentum Sentiment Has been gaining momentum

Activity

×

Activity

RPRX Activity Sentiment Pays a reliable dividend

Future

×

Future

RPRX Future Sentiment Earnings are forecast to grow
RPRX Analysts Opinion

RPRX Analysts opinion is positive and also has improved from the past 3 months

RPRX Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

100%
Consensus Rating
NA
Buy
Opinion
NA
Trend
Score
100%
Potential
Score
RPRX Street Sentiment

RPRX Street Sentiment is extremely bullish and have positive views on the near-term outlook

RPRX Risk Level

RPRX has Low risk level

RPRX Risk Level
Low
LOW
HIGH
RPRX Performance Sentiment
Sentiments overview associated with events and the stock performance.
100%
Positive
10 out of 10
events present
0%
Negative
0 out of 10
events present
Very Bullish
Bullish
Neutral
Bearish
Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price
$41.38
Resistance Price
$47.47
Current Price Range
$47.47
$41.38
$47.47
Show methods +

Latest Analyst Actions

Overall Wall Street Rating

100%
Consensus Rating
STRONG BUY
4
Buy
0
Hold
0
Sell
Date
Action
Rating
Firm
Feb 10, 2026
Upgrade
Buy
Citi
Dec 12, 2025
Reiterate
Buy
TD Cowen
Oct 11, 2025
Reiterate
Overweight
Morgan Stanley
Sep 30, 2025
Initiate
Buy
Goldman Sachs
 
 
 
 

RPRX Stock IQ

 
 
 
lock  Login to unlock Royalty Pharma plc (RPRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
 
 
 

Target Price

 
 
 
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 
 

RPRX Rewards

 Earnings are forecast to grow

RPRX Rewards

 Pays a reliable dividend

 
 
 

RPRX Latest Analysis

 
 
 

Zymeworks Reports FY25 Results Secures $250 Million Royalty Financing . (RTTNews) - Zymeworks Inc. (ZYME) has reported its fourth-quarter and full-year 2025 financial results while announcing a major $250 million royalty-backed financing agreement with Royalty Pharma strengthening its balance sheet and extending its cash runway beyond 2028.

 

Mon Mar 2, 2026

$47.47 | +2.73%
 
Activity

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing. Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks'. balance sheet with non-di

 

Mon Mar 2, 2026

$47.47 | +2.73%
 
Activity

Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma . (RTTNews) - Zymeworks Inc. (ZYME) a clinical-stage biopharmaceutical company on Monday entered into a $250 million royalty funding agreement with Royalty Pharma plc (RPRX) a buyer of biopharmaceutical royalties through a non-recourse royalty-backed note secured by a portion o

 

Mon Mar 2, 2026

$47.47 | +2.73%
 
Activity

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing. VANCOUVER British Columbia and NEW YORK March 02 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and Be

 

Mon Mar 2, 2026

$47.47 | +2.73%
 
Activity
 
 
 
 
 
StocksRunner

Discover RPRX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of RPRX. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our RPRX Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

RPRX Stock trends

RPRX Stock performance

RPRX Stock analysis

RPRX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 

RPRX Alerts

Real-time signals powered by data
×

Price-Based

Triggers when the stock breaks through a known resistance level
 
Triggers when the stock drops below a key support level
 
Notifies if the stock moves up/down by a set percentage (e.g. ±5%)
 
Alerts when the stock hits a new high or low
 
Signals proximity to long-term highs or lows (e.g. within 5%)
 

Technical Indicator (Pro Plan)

Volume spikes 2x–3x above average. Indicates strong buying/selling pressure
 
Tracks large intraday swings, signaling potential opportunities or risk
 
Signals potential trend reversals or continuations
 
Long-term bullish/bearish trend signals from MA crossovers
 
RSI above 70 or below 30 to identify possible reversals
 
Signals momentum shifts
 

Fundamental Indicator (Master Plan)

Upcoming or just-released earnings reports
 
Alerts after results compared to expectations
 
Changes in rating or target price
 
New or changed dividends
 
Large trades by company insiders
 
M&A, lawsuits, product launches, etc
 
High volume/open interest in call/put contracts
 
Surge in mentions or sentiment shifts
 
 
Cancel
 
×
 
0/666
joker
 
Post
 
✕
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing RPRX

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

 
✕
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing RPRX

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.